Improve Medical(SZ:300030)2026-01-28 08:26Financial Performance Expectations - The company expects a net profit of between 12 million and 17.5 million yuan for 2025, a significant turnaround from a loss of 117.9 million yuan in the same period last year[4] - The net profit after deducting non-recurring gains and losses is projected to be between 16.5 million and 24 million yuan, compared to a loss of 69.98 million yuan in the previous year[4] - Non-recurring gains and losses are expected to negatively impact net profit attributable to shareholders by 5 million to 7.5 million yuan, a significant improvement from the previous year's impact of 47.93 million yuan[7] Revenue and Sales Outlook - The company's operating revenue is expected to decline by 15% to 20% year-on-year, primarily due to decreased sales of vacuum blood collection system products[6] Cost Management and Profitability - Despite the decline in product prices, the company has successfully improved its gross margin slightly year-on-year through systematic cost optimization and refined management[6] - The company anticipates a decrease in impairment losses for goodwill, inventory, fixed assets, and credit losses compared to the previous year[7] Investment and Income - Investment income is expected to increase year-on-year, mainly due to the company's stake in Shenzhen Yanghe Biomedical Industry Investment Co., which holds shares in Nanjing Weisi Medical Technology Co., Ltd.[7] Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with the final figures to be disclosed in the official 2025 annual report[8]